NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.
For Professional Investors Only (at this time)2022-11-16T06:36:13+00:00

Professional Investors Only

Normax Story in 5 minutes…

The Mission of Normax (1:00)

Vax Factory by Normax (1:35)

Normax mRNA Vaccines (1:00)

SARS-CoV-2 mRNA Vaccine R&D (1:40)

Invest in NRMX for Competitive Projected Financial Performance (Alpha) with Transformative Local and Global Social Impact (1)

Biomedical Facts:

  • mRNA is Nature: DNA mRNA Proteins All Life on Earth
  • Healthcare is a Forever Business: of about 10,000 diseases, only about 500 are currently treatable
  • Cost of COVID-19 (2020-22): 22 Million Lives Lost + $28 Trillion Dollars Lost + 100 Million People Disabled by Long Covid (2)
  • Pandemic Preparedness: Pathogens and outbreaks are inevitable. Pandemics are not. (3)
  • SARS-CoV-2 Evolution: Dangerous, Continuous, Uncontrollable Global Evolution of Multiple SARS-CoV-2 “Variants of Concern” Toward Immune Escape with Unpredictable Consequences. (4)
  • mRNA Technology: Applicable, in principle, to the treatment of diverse clinical indications. (5)(6)

NRMX ESG Value Creation:

  • mRNA Vaccines for Infectious Diseases
  • mRNA Vaccines for Rare Diseases
  • Personalized mRNA Vaccines for Cancers
  • mRNA Vaccine Infrastructure for Pandemic Preparedness (7)
  • Safe and Effective Regulatory Approved Vaccines Save Lives (8)

NRMX Capital Investment Plan:

  • $2.5 Billion: 100 mRNA Vaccines x $25 Million average R&D investment per mRNA Vaccine (9)
  • $2.5 Billion: 100 Vax Factories x $25 Million average infrastructure investment per Vax Factory (10)

  • $5.0 Billion: 25% equity, 75% vaccine bonds (11) (12)

NOTES:

  1. Professional Investors Only. Prospectus available on request. Forward-looking statement. Capital at risk. Normax core business: mRNA Vaccine R&D and Manufacturing.
  2. COST of COVID-19: The Economist. 22 Million Lives Lost. IMF. $28 Trillion Dollars Lost. BMJ. 100 Million People Disabled by Long Covid.
  3. Pandemic preparedness is vital for safety, prosperity and stability. Our common industry goal is to develop safe and effective new mRNA Vaccines in less than 100 days.
  4. Learn more about ongoing global evolution of SARS-CoV-2 “Variants of Concern”.
  5. NATURE BIOTECHNOLOGY. REVIEW. Unlocking the promise of mRNA therapeutics – 03 November 2022
  6. SCIENCE TRANSLATIONAL MEDICINE. VIEWPOINT. Vaccines 2020: The era of the digital vaccine is here – 15 Dec 2021
  7. Learn More: No Pandemics. Normax.
  8. For the first year of vaccines, over 20 million lives are estimated to have been saved around the world December 2020-21. The Lancet
  9. Normax average investment per mRNA Vaccine R&D. Estimated average value per regulatory approved vaccine product can be up to $1 Billion, or more.
  10. Normax average investment per Vax Factory, excluding land and warehousing facilities. “CDMO” fee-for-service business estimated average EBITDA 30-40%
  11. Not an offer. See prospectus for professional investors only.
  12. Normax Biomed (Ticker: NRMX) plans for a Primary Direct Listing (PDL) on SIX Sparks (Q1/2 2023) and Nasdaq (Q3/4 2023). Nasdaq permits private companies to undergo a primary direct listing on the exchange, which is referred to as a “Direct Listing with a Capital Raise.”

MEET US

CONTACT US

NRMX PRIMARY INVESTORS

  • Professional Investors
  • Institutional Investors
  • Sovereign Wealth Fund Investors
  • Family Office Investors
  • Foundation Investors (Program Related)

NRMX DATA ROOM CONTENT

AVAILABLE on REQUEST by PROFESSIONAL INVESTORS ONLY

  • NRMX DECK. Available for Informational Purposes.
  • NRMX FTO (Freedom To Operate). Confidential Independent Opinion.
  • NRMX VALUATION. Confidential Independent Opinion.
  • NRMX PROSPECTUS for Primary Direct Listing on SIX Sparks (Q1 2023)

WHY INVEST IN NRMX?

  • Equal Access and Transparent Primary Direct Listing (PDL) Offering
  • Competitive Projected Financial Performance of NRMX Business
  • Exceptional Local and Global Social Impact Opportunity of mRNA Vaccines
  • Regulatory Compliant PDL Offering on Regulated Market Exchanges
  • Safe and Effective Regulatory Approved Vaccines Save Lives and Spare Healthcare Resources and can help Prevent Pandemics in the Future

NRMX LISTING PLAN: SIX SPARKS

  • SIX Sparks. 20% Float
  • STAGE 1: Primary Direct Listing Offering in Q1 and Q2 2023
  • “Sparks – The new stock exchange venue exclusively for SMEs. Equities listed on Sparks are traded on a regulated exchange — SIX Swiss Exchange. All SMEs on Sparks are subject to the same supervision and provisions as companies traded on the main market, which means that investors benefit from the same level of transparency and regulatory oversight. The listing status also enables pension funds to allocate these Sparks shares to their equities quota.” – SIX Swiss Exchange

NRMX LISTING PLAN: NASDAQ

  • Nasdaq. +20% Float
  • STAGE 2: Primary Direct Listing Offering planned in Q3 and Q4 2023
  • “Nasdaq Direct Listings offer a different way to go public with unrestricted liquidity and no lock-up period. The SEC recently approved Nasdaq’s rule filing to permit a company to conduct a direct listing on our market in connection with a primary capital raise. Nasdaq is the only exchange that provides order book transparency through our technology solution called the Bookviewer. Everything we offer clients in an IPO, we offer in a direct listing.” – Nasdaq

NRMX LEGAL ADVISORS

NRMX GLOBAL MEDIA AGENT

SUMMARY OF NORMAX 300 MILLION SHARE SUBSCRIPTION FACILITY

Normax secures €300,000,000 capital commitment from Global Emerging Markets (GEM) for research and development and manufacturing of mRNA Vaccines for transformative global social impact

July 11, 2022, 12:00 PM Greenwich Mean Time (GMT) – PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER.

  • DUBLIN, Ireland — The mRNA vaccine technology company Normax Biomed Limited (“Normax”), today announced a €300 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), the $3.4 Billion, Luxembourg based, private alternative investment group that focuses on emerging markets with offices in Paris, Nassau (Bahamas) and New York.
  • Under the agreement, GEM will provide Normax with a Share Subscription Facility (“SSF”) of up to €50 Million for a 36 month term following the public listing of the Normax common stock, and an SSF of up to €250 Million for up to ten specialized Normax Subsidiary Companies (“SPV”) of Normax Group. Normax will control the timing and maximum amount of each drawdown under the facility and has no minimum subscription obligation. Normax plans to list on SIX Swiss Exchange and/or SIX Digital Exchange (SDX) and/or London Stock Exchange with digital Normax mRNA Vaccine and Vax Factory SPV listings on SDX.
  • The SSF entered into with GEM Global Yield LLC SCS, Luxembourg, and GEM Yield Bahamas Ltd (collectively “GEM”) is a EUR 300 million facility over three (3) years and allows Normax to draw down funds at its option in exchange for Normax common shares. The mechanics of the GEM facility allow for multiple draw-downs, the amount being in a range related to the trading volume and price of the Normax shares. Normax will control the timing and maximum amount of any draw-down, and has the right, not the obligation, to draw down on the full committed amount. The draw-down amount is based on 90% of the average closing price and the average volume of the Normax common shares of the last 15 trading days. The consideration for the GEM facility is due for payment by Normax in twelve months from the listing of the shares on SIX Swiss Exchange and can be paid by way of Normax shares. In addition, GEM has been granted warrants to purchase Normax shares.
  • “Normax is on a social mission to redress global healthcare inequity caused by the profiteering pharmaceutical industry. Following our €300 million capital commitment in Normax, we plan to deliver research and development of mRNA vaccines for COVID, TB, HIV, and Malaria and deploy modular mRNA Vaccine Factories, ultimately in up to 100 locations. In the event of another public health emergency we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will all suffer through. Deadly diseases wait for no man and no market. Despite adverse market conditions Normax will go to market in 2023 because it’s the right thing to do. This can be good news for investors seeking fundamental value opportunities. Our Normax core business of mRNA vaccine R&D and manufacturing can deliver sustainable returns on fundamental healthcare needs that biologically will last forever. Pathogens are inevitable, but diseases are not,” says Peter A. Jensen, CEO and Chairman of Normax.

LISTED PEERS (public market reference data)

TICKER MARKET CAP (11.11.22) LINK
MRNA $65.7 Billion Moderna, Inc.
BNTX $37.5 Billion BioNTech SE
ALNY $26.6 Billion Alnylam Pharmaceuticals, Inc.
SRPT $9.3   Billion Sarepta Therapeutics, Inc.
IONS $6.1   Billion Ionis Pharmaceuticals, Inc.
ARWR $3.6  Billion Arrowhead Pharmaceuticals, Inc.
CVAC $1.3  Billion CureVac N.V.
ARCT $0.5 Billion Arcturus Therapeutics Holdings Inc.

Normax Professional Investor Events in November 2022

NOV 14

NOV 15 & 17

NOV 16

IMPORTANT DISCLOSURE FOR PROFESSIONAL INVESTORS

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the relevant Stock Exchange by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the relevant Stock Exchange.

In the United Kingdom, this communication is issued by ECAM Biomed Global Impact Limited and approved by Robert Quinn Advisory LLP, which is authorised and regulated by the UK Financial Conduct Authority (“FCA”). ECAM Biomed Global Impact Limited is an Appointed Representative of Robert Quinn Advisory LLP. This material constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 (the “Act”) and the handbook of rules and guidance issued from time to time by the FCA (the “FCA Rules”). This material is for information purposes only and does not constitute an offer to subscribe for or purchase of any financial instrument. ECAM Biomed Global Impact Limited neither provides investment advice to, nor receives and transmits orders from, persons to whom this material is communicated nor does it carry on any other activities with or for such persons that constitute “MiFID or equivalent third country business” for the purposes of the FCA Rules. All information provided is not warranted as to completeness or accuracy and is subject to changes without notice. This communication and any investment or service to which this material may relate is exclusively intended for persons who are Professional Clients or Eligible Counterparties for the purposes of the FCA Rules and other persons should not act or rely on it. This communication is not intended for use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

Go to Top